Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CRTE7A2 01 T cell receptor T-cell therapy - Beijing Kerui Biotechnology

Next Previous
Drug Profile

CRTE7A2 01 T cell receptor T-cell therapy - Beijing Kerui Biotechnology

Alternative Names: CRTE7A2 01 T cell receptor T-cell therapy - CorreGene; CRTE7A2 01 TCR; CRTE7A2 01 TCR therapy; CRTE7A2-01 TCR T-cell therapy

Latest Information Update: 12 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Kerui Biotechnology
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anal cancer; Cervical cancer; Head and neck cancer

Most Recent Events

  • 12 Apr 2024 Corregene Biotechnology plans a phase I trial for Head and Neck cancer, Cervical cancer and Anal cancer (Late stage disease, Metastatic disease, Second line therapy or greater) (parentral) in April 2024 (NCT06358053)
  • 28 Jun 2022 Phase-I clinical trials in Anal cancer (Second-line therapy or greater, Combination therapy, Late-stage disease) in China (IV) (NCT05122221)
  • 28 Jun 2022 Phase-I clinical trials in Cervical cancer (Second-line therapy or greater, Combination therapy, Late-stage disease) in China (IV) (NCT05122221)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top